Exelixis (EXEL) Gross Profit Growth (3y) (2015 - 2026)

Exelixis (EXEL) Gross Profit Growth (3y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Profit Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 54.36%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 7.16%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 3.86%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 79.18%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Exelixis 14.44 Bn 13.66 Bn 590.86 Mn 14.42%

Historic Data

Download Data
DateValue
Apr 3, 2026 14.42%
Jan 2, 2026 11.93%
Oct 3, 2025 13.47%
Jul 4, 2025 10.57%
Apr 4, 2025 16.09%
Sep 27, 2024 18.16%
Jun 28, 2024 18.71%
Mar 29, 2024 16.27%
Dec 29, 2023 21.33%
Sep 29, 2023 26.78%
Jun 30, 2023 21.79%
Mar 31, 2023 21.93%
Sep 30, 2022 14.49%
Jul 1, 2022 20.37%
Apr 1, 2022 18.12%
Oct 1, 2021 13.23%
Jul 2, 2021 27.16%
Apr 2, 2021 7.30%
Jan 1, 2021 30.30%
Oct 2, 2020 14.57%